JP2002543144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002543144A5 JP2002543144A5 JP2000615025A JP2000615025A JP2002543144A5 JP 2002543144 A5 JP2002543144 A5 JP 2002543144A5 JP 2000615025 A JP2000615025 A JP 2000615025A JP 2000615025 A JP2000615025 A JP 2000615025A JP 2002543144 A5 JP2002543144 A5 JP 2002543144A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- hydrogen
- embedded image
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 57
- 229910052739 hydrogen Inorganic materials 0.000 description 36
- 239000001257 hydrogen Substances 0.000 description 36
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 150000002431 hydrogen Chemical class 0.000 description 20
- -1 6-Naphthyl Chemical group 0.000 description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 229910052736 halogen Inorganic materials 0.000 description 16
- 150000002367 halogens Chemical class 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 14
- 125000006163 5-membered heteroaryl group Chemical class 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 108010050904 Interferons Proteins 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 125000005982 diphenylmethyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 6
- 125000003373 pyrazinyl group Chemical group 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 102100040018 Interferon alpha-2 Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010079944 Interferon-alpha2b Proteins 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000001624 naphthyl group Chemical class 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 0 CC1*C(CN)C1 Chemical compound CC1*C(CN)C1 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- LOWSGZSXTWOIEH-UHFFFAOYSA-N CC1=CC=C=C1 Chemical compound CC1=CC=C=C1 LOWSGZSXTWOIEH-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30489799A | 1999-05-04 | 1999-05-04 | |
| US09/304,897 | 1999-05-04 | ||
| PCT/US2000/011634 WO2000066141A2 (en) | 1999-05-04 | 2000-05-01 | Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002543144A JP2002543144A (ja) | 2002-12-17 |
| JP2002543144A5 true JP2002543144A5 (https=) | 2007-06-21 |
Family
ID=23178462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000615025A Ceased JP2002543144A (ja) | 1999-05-04 | 2000-05-01 | ＰＥＧ化インターフェロンαＣＣＲ５アンタゴニスト併用ＨＩＶ療法 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1175224B1 (https=) |
| JP (1) | JP2002543144A (https=) |
| CN (1) | CN1349408A (https=) |
| AR (1) | AR023824A1 (https=) |
| AT (1) | ATE289516T1 (https=) |
| AU (1) | AU776541B2 (https=) |
| BR (1) | BR0010593A (https=) |
| CA (1) | CA2365900A1 (https=) |
| DE (1) | DE60018273T2 (https=) |
| ES (1) | ES2238277T3 (https=) |
| HK (1) | HK1039278B (https=) |
| HU (1) | HUP0202734A3 (https=) |
| MX (1) | MXPA01011116A (https=) |
| MY (1) | MY127670A (https=) |
| NO (1) | NO328679B1 (https=) |
| NZ (1) | NZ514519A (https=) |
| PE (1) | PE20010283A1 (https=) |
| PT (1) | PT1175224E (https=) |
| TW (1) | TWI289454B (https=) |
| WO (1) | WO2000066141A2 (https=) |
| ZA (1) | ZA200108870B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US7498323B2 (en) | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
| US20070043079A1 (en) * | 2003-04-18 | 2007-02-22 | Hiromu Habashita | Heterocyclic compound containing nitrogen atom and use thereof |
| ES2294589T3 (es) | 2004-04-29 | 2008-04-01 | F. Hoffmann-La Roche Ag | Variacion de la secuencia nucleosida de ns5a como marcador. |
| EP1790637B1 (en) | 2004-09-13 | 2014-01-29 | Ono Pharmaceutical Co., Ltd. | Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient |
| JP4769257B2 (ja) * | 2005-02-23 | 2011-09-07 | シェーリング コーポレイション | ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体 |
| US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
| PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| KR20090008217A (ko) | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
| EP2042503B1 (en) | 2006-05-16 | 2013-01-30 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
| WO2008016006A1 (fr) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| AU2012338581B2 (en) | 2011-11-18 | 2016-12-08 | Nxera Pharma Uk Limited | Muscarinic M1 receptor agonists |
| BR112016015736B1 (pt) * | 2014-01-08 | 2022-01-04 | Immunovative Therapies, Ltd. | Uso de um aloantígeno, uma molécula que interage com receptor de superfície cd40 e citocinas tipo i; e pelo menos um ou mais antígenos de hiv, kit, composição e composição de avi |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| PT858343E (pt) * | 1995-11-02 | 2004-07-30 | Schering Corp | Terapia por infusao continua de uma dose baixa de citoquina |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| AU5522498A (en) * | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
-
2000
- 2000-05-01 CN CN00807116A patent/CN1349408A/zh active Pending
- 2000-05-01 ES ES00928604T patent/ES2238277T3/es not_active Expired - Lifetime
- 2000-05-01 HU HU0202734A patent/HUP0202734A3/hu unknown
- 2000-05-01 HK HK02100826.8A patent/HK1039278B/en not_active IP Right Cessation
- 2000-05-01 BR BR0010593-7A patent/BR0010593A/pt not_active Application Discontinuation
- 2000-05-01 DE DE60018273T patent/DE60018273T2/de not_active Expired - Lifetime
- 2000-05-01 AT AT00928604T patent/ATE289516T1/de not_active IP Right Cessation
- 2000-05-01 JP JP2000615025A patent/JP2002543144A/ja not_active Ceased
- 2000-05-01 AU AU46815/00A patent/AU776541B2/en not_active Ceased
- 2000-05-01 NZ NZ514519A patent/NZ514519A/en not_active IP Right Cessation
- 2000-05-01 EP EP00928604A patent/EP1175224B1/en not_active Expired - Lifetime
- 2000-05-01 WO PCT/US2000/011634 patent/WO2000066141A2/en not_active Ceased
- 2000-05-01 PT PT00928604T patent/PT1175224E/pt unknown
- 2000-05-01 MX MXPA01011116A patent/MXPA01011116A/es active IP Right Grant
- 2000-05-01 CA CA002365900A patent/CA2365900A1/en not_active Abandoned
- 2000-05-02 MY MYPI20001893A patent/MY127670A/en unknown
- 2000-05-02 PE PE2000000408A patent/PE20010283A1/es not_active Application Discontinuation
- 2000-05-02 AR ARP000102097A patent/AR023824A1/es unknown
- 2000-05-02 TW TW089108323A patent/TWI289454B/zh not_active IP Right Cessation
-
2001
- 2001-10-26 ZA ZA200108870A patent/ZA200108870B/xx unknown
- 2001-11-02 NO NO20015367A patent/NO328679B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002543144A5 (https=) | ||
| US7115578B2 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| US6525033B1 (en) | Nucleosides with anti-hepatitis B virus activity | |
| US6277830B1 (en) | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon | |
| US6403564B1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| US6495677B1 (en) | Nucleoside compounds | |
| KR20070102741A (ko) | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| JP2004509061A5 (https=) | ||
| DE60018273T2 (de) | Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie | |
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2005533824A5 (https=) | ||
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| JP2004533401A5 (https=) | ||
| HK1255463A1 (zh) | Hbv衣壳组装抑制剂和干扰素的组合疗法 | |
| RU2001132635A (ru) | Производные пиперидина, применимые в качестве антагонистов сс R5 | |
| CA2632626A1 (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2018531272A6 (ja) | Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法 | |
| JP2818299B2 (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
| US20030004119A1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| EP1121369B1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| JP2002527522A5 (https=) | ||
| PT1284720E (pt) | L-fmau para o tratamento de infecção viral por hepatite delta | |
| EP1382343B1 (en) | Combination therapy to treat hepatitis B virus | |
| EP3999069B1 (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection |